Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive September 1, 2012 Thomas Baker	The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support.
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Chemistry World June 5, 2009 Anna Lewcock	Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive November 1, 2012 Greg Lovas	The Battle's on for HR Success in China Chinese start-ups have realized that they need to recruit highly skilled and globally oriented general managers from foreign multinationals when they reach a critical size.
Pharmaceutical Executive October 1, 2006 Ray Hill	China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
Chemistry World July 29, 2013 Hepeng Jia	China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Pharmaceutical Executive October 1, 2012 Nicolas Pechet	Your Local Competitor: A Threat in Emerging Markets? Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions.
Pharmaceutical Executive August 1, 2011 William Looney	Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
Pharmaceutical Executive August 1, 2005 Lena Chow	Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market.
Pharmaceutical Executive October 1, 2012	Country Report: Turkey In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. The pharmaceutical industry has also enjoyed a wave of expansion.
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive September 1, 2008 Patrick Clinton	Attack of the Junk The United States makes the best medicines in the world. In days to come, that could be a problem.
Chemistry World November 18, 2010 Ned Stafford	New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system.
Pharmaceutical Executive February 1, 2011 Stan Bernard	Are You Trained to Compete and Win? With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Pharmaceutical Executive April 1, 2012	Country Report: Ukraine Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts. But what has such rapid development done for the country's healthcare?
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive July 1, 2013	Country Report: Colombia Colombia is focusing on bolstering the commercial sector. While this is good news for the pharmaceutical industry, there is still a strong debate about how healthcare in Colombia can be improved.
Pharmaceutical Executive August 1, 2013 Joseph Saba	New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
BusinessWeek March 4, 2010 Frederik Balfour	The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care.
Pharmaceutical Executive January 1, 2013 Jill Wechsler	Transformation to Characterize 2013 FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
The Motley Fool October 11, 2011 Cliff D'Arcy	AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China.
Pharmaceutical Executive March 1, 2007 Kim D. Slocum	Opinion: Trigger Points Timing is everything. But when is it right? As pharma begins to confront the looming issue of sales-force downsizing, execs should keep an eye on six factors that can help answer that very question.
Pharmaceutical Executive June 1, 2013	When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.
CRM November 1, 2007 Woody Driggs	The Year (and Decade) of the Tiger Think you can translate your brand for the savvy Chinese shopper?
Pharmaceutical Executive August 1, 2012	Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years.
Pharmaceutical Executive April 1, 2011	Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Pharmaceutical Executive December 1, 2006 Rod Cavin	Forecasting Medicare: Price Controls in the Years Ahead Part D in 2010 will be under price and access pressure. Pharma should develop plans for the future by imagining best- and worst-case scenarios.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Pharmaceutical Executive October 1, 2005	Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies.
Pharmaceutical Executive May 1, 2011	Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement.
HBS Working Knowledge July 30, 2008 Mihir A. Desai	Why the U.S. Should Encourage FDI American financial executives are courting foreign direct investors, particularly sovereign wealth funds, for new investments. Should these investments draw increased scrutiny from U.S. regulators? Economics says that FDI should be encouraged.
Pharmaceutical Executive August 1, 2008	Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how.
HBS Working Knowledge July 11, 2005 Garry Emmons	The New International Style of Management As the best international companies exhibit similarities in certain standards and practices, managers within these firms, despite national and cultural differences, are finding common ground where they can work together.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.